Influence of CYP2C19 genetic variants on clopidogrel in healthy subjects

Trial Profile

Influence of CYP2C19 genetic variants on clopidogrel in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2012

At a glance

  • Drugs Clopidogrel (Primary)
  • Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Peripheral arterial occlusive disorders; Stroke
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms CLOVIS
  • Most Recent Events

    • 05 Jul 2012 Last checked against European Clinical Trials Database record.
    • 05 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 May 2011 Planned number of patients changed from 30 to 140.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top